The class I HDAC inhibitor romidepsin (FDA approved for relapsed PTCL) alone was highly effective as evident by 80% decrease in cell survival as compared to control. Here, HDAC9 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.